Mechanisms of disease: Inflammatory mediators and cancer prevention

Nature Clinical Practice Oncology

Volumn 2, Issue 4, 2005, Pages 202-210

  Mann, Jason R ^a   Backlund, Michael G ^b   DuBois, Raymond N ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

15 PGDH; Cancer; Chemoprevention; Cyclooxygenase 2; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DICLOFENAC; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOLIC ACID; GEFITINIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LIPID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; ROFECOXIB; SELENIUM; SULINDAC; TAMOXIFEN; VALDECOXIB;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL STIMULATION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DYSPEPSIA; FAMILIAL DISEASE; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR DYNAMICS; NAUSEA; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STROKE; THROMBOSIS; TREATMENT OUTCOME; ULCER PERFORATION;

HUMANS; INFLAMMATION MEDIATORS; NEOPLASMS;

EID: 20444463535     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0140     Document Type: Review

References (55)

1. Edwards BK et al. (2002) Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 94: 2766-2792
2. Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36 (Pt 2): 2699-2702
3. Sabichi AL et al. (2003) Frontiers in cancer prevention research. Cancer Res 63: 5649-5655
4. Sudbo J et al. (2001) DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344: 1270-1278
5. Fisher B et al. (11998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
6. Steinbach G et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952
7. Tsao AS et al. (2004) Chemoprevention of cancer. CA Cancer J Clin 54: 150-180
8. Saltz LB et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
9. Eberhart CE et al. (1994) Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
10. Gupta RA and DuBois FIN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21
11. Marnett LJ and DuBois FIN (2002) COX-2: A target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42: 55-80
12. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232-235
13. Shureiqi I et al. (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850
14. Benamouzig R et al. (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125: 328-336
15. Smalley WE and DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39: 1-20
16. Thun MJ et al. (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596
17. Sandler RS et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890
18. Baron JA et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899
19. DuBois RN et al. (1996) Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterol Clin North Am 25: 773-791
20. Giardiello FM et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316
21. Labayle D et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639
22. Steinbach G et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952
23. Giardiello FM et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059
24. Wolfe MM et al. (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899
25. Taha AS et al. (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334: 1435-1439
26. Laine L et al. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117: 776-783
27. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528
28. Grover JK et al. (2003) Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 18: 279-291
29. Hernandez MR et al. (2004) Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. Eur J Clin Invest 34: 297-302
30. Brinker A et al. (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21: 479-484
31. Kimmel SE et al. (2005) Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157-164
32. Bresalier R et al. (2004) Rofecoxib APPROVe Study Results and Their Implications. In 2004 ACR/ARHP Annual Scientific Meeting: 2004, October 16-21; Texas
33. Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255
34. Tortora G et al. (2003) Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9: 1566-1572
35. Torrance CJ et al.] (2000) Combinatorial chemoprevention of intestinal neoplasia. Nature Med 6: 1024-1028
36. Baselga J et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
37. Rigas B et al. (11993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523
38. Turini ME and DuBois RN (2002) Cyclooxygenase-2: a Therapeutic target. Annu Rev Med 53: 35-57
39. Hansen-Petrik MB et al. (2002) Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403-408
40. Kawamori T et al. (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985-990
41. Wang D et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295
42. Watanabe K et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096
43. Mutoh M et al. (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62: 28-32
44. Sonoshita M et al. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat Med 7: 1048-1051
45. Quidville V et al. (2004) Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 145: 2561-2571
46. Gee JR et al. (2003) Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 21: 266-270
47. Backlund MG et al. (2005) 15-hydroxyprostaglandin dehydrogenase is downregulated in colorectal cancer. J Biol Chem 280: 3217-3223
48. Davis TW et al. (2004) Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64: 279-285
49. Liu W et al. (2003) Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26: S103-S109
50. Rich TA and Shepard R (2003) COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. Am J Clin Oncol 26: S110-S113
51. Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med [doi: 10.1056/NEJMoa050405]
52. Bresalier IRS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med [doi: 10.1056/NEJMoa050493]
53. Nussmeier NA et al. (2005) Complications of the COX-2 Inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med [doi: 10.1056/NEJMoa050330]
54. Gann PH et al. (11993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220-1224
55. Ladenheim J et al. (1995) Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083-1087